Envista’s first quarter results saw sales increase driven by strong growth across orthodontics, diagnostics, and consumables, supported by new product launches and operational improvements. However, the negative market reaction reflected investor caution, as management pointed to macroeconomic uncertainty and the impact of tariffs as ongoing challenges. CEO Paul Keel noted the company’s gains “were partly due to improved execution in growth, operations, and people,” while also acknowledging the benefits from additional billing days and focused cost controls.

Is now the time to buy NVST? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Envista’s Q1 Earnings Call

• Elizabeth Anderson (Evercore ISI) asked about the drivers behind Envista’s recent momentum and challenges in areas gaining traction. CEO Paul Keel cited investments in clinical education, cost controls, and new product development as key, while highlighting macro uncertainty as a persistent challenge.
• Michael Cherny (Leerink Partners) inquired about the timeline and guidance assumptions for China’s VBP in implants and orthodontics. CFO Eric Hammes said guidance assumes VBP begins in Q2 or Q3, with ongoing monitoring of market developments.
• Jeffrey Johnson (Baird) questioned the extent of VBP-related headwinds in China and future pricing actions. Keel and Hammes detailed ongoing channel destocking and noted future price increases will be considered if inflation pressures intensify.
• Michael Sarcone (Jefferies) asked about inflation risks from Middle East tensions and mitigation strategies. Keel explained that fuel and input cost exposures are limited, with task forces in place to manage logistics and supply chain shifts.
• Jonathan Block (Stifel) sought clarity on the step-up in growth investments and durability of outperformance in equipment and consumables. Keel emphasized reinvestment of margin gains into product development, attributing outperformance to strong infection prevention products and diagnostic software advances.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will monitor (1) the pace of adoption and clinical feedback for new Spark clear aligner markets and DEXIS AI-powered diagnostics, (2) the operational impact and revenue cadence from tariffs and China’s VBP rollout, and (3) the ability of Envista’s supply chain initiatives to offset inflation and input cost volatility. Progress on international expansion and new product commercialization will also be key signposts.

Envista currently trades at $24.29, down from $27.07 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

The Best Stocks for High-Quality Investors

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.